Verastem Inc. (VSTM)’s Financial Results Comparing With Trillium Therapeutics Inc. (NASDAQ:TRIL)

Both Verastem Inc. (NASDAQ:VSTM) and Trillium Therapeutics Inc. (NASDAQ:TRIL) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Verastem Inc. 2 4.62 N/A -1.26 0.00
Trillium Therapeutics Inc. N/A 0.00 N/A -2.55 0.00

Demonstrates Verastem Inc. and Trillium Therapeutics Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 has Verastem Inc. and Trillium Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Verastem Inc. 0.00% -80% -40.8%
Trillium Therapeutics Inc. 0.00% 0% 0%

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Verastem Inc. and Trillium Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Verastem Inc. 0 0 3 3.00
Trillium Therapeutics Inc. 0 0 0 0.00

Verastem Inc.’s upside potential is 422.39% at a $7 consensus price target.

Institutional and Insider Ownership

Institutional investors held 47% of Verastem Inc. shares and 40.67% of Trillium Therapeutics Inc. shares. About 0.4% of Verastem Inc.’s share are held by insiders. Competitively, Trillium Therapeutics Inc. has 0.26% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Verastem Inc. 13.64% 6.38% -28.23% -53.42% -80.05% -55.36%
Trillium Therapeutics Inc. -1.69% 4.05% -38.77% -80.06% -93.02% -79.59%

For the past year Verastem Inc. has stronger performance than Trillium Therapeutics Inc.

Summary

Verastem Inc. beats Trillium Therapeutics Inc. on 6 of the 8 factors.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The companyÂ’s defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. The companyÂ’s duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma. The company has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.